Strength training and growth hormone: effects on bone of Wistar rats

Author(s):  
Robson Chacon Castoldi ◽  
Ines Cristina Giometti ◽  
Guilherme Akio Tamura Ozaki ◽  
Thiago Alves Garcia ◽  
Melise Jacon Peres Ueno ◽  
...  
2019 ◽  
Vol 37 (1) ◽  
pp. 104-110
Author(s):  
Heliard Rodrigues dos Santos Caetano ◽  
Robson Chacon Castoldi ◽  
Éverton Alex Carvalho Zanuto ◽  
Guilherme Akio Tamura Ozaki ◽  
Thiago Alves Garcia ◽  
...  

1980 ◽  
Vol 87 (2) ◽  
pp. 303-312 ◽  
Author(s):  
P. MARY COTES ◽  
W. A. BARTLETT ◽  
ROSE E. GAINES DAS ◽  
P. FLECKNELL ◽  
R. TERMEER

Different methods for administration of human growth hormone (hGH) have been examined with a view to efficient use of the limited amounts of hGH at present available for clinical use. We found that in hypophysectomized rats (1) hGH administered by continuous subcutaneous infusion induced a greater increase in body weight (referred to throughout as growth) than hGH administered by intermittent (daily) injection and (2) intermittent injections of hGH dissolved in 16% gelatin induced more growth than hGH dissolved in a glycine buffer. It was further found that (1) hGH dissolved in 16% gelatin compared with hGH dissolved in a glycine buffer induced lower maximal levels of immunoreactive plasma hGH and between 7 and 9 h after treatment higher plasma levels when injected subcutaneously in rabbits, (2) 125I-labelled hGH added as a tracer to hGH in gelatin was removed more slowly from subcutaneous injection sites in rabbits than 125I-labelled hGH given with hGH in glycine buffer and (3) changes in the ratio of hGH to gelatin had little effect on the time-course of plasma levels of hGH in the rabbit. Addition of the protease inhibitors aprotinin or 6-aminohexanoic acid, to injection of hGH in gelatin or glycine did not induce any consistent increase in plasma levels of hGH.


2013 ◽  
Vol 35 (2) ◽  
pp. 283-291 ◽  
Author(s):  
Leonardo Vidal Andreato ◽  
João Victor Del Conti Esteves ◽  
Felipe Natali Almeida ◽  
Tatiane Aparecida da Silva Ribeiro ◽  
Helenton Cristhian Barrena ◽  
...  

2002 ◽  
Vol 93 (6) ◽  
pp. 2034-2037 ◽  
Author(s):  
H. Cavalié ◽  
G. Lac ◽  
P. Lebecque ◽  
B. Chanteranne ◽  
M.-J. Davicco ◽  
...  

This paper reports that the selective β2-adrenergic receptor agonist clenbuterol affects bone metabolism in growing 3-mo-old male Wistar rats treated over 8 wk. Thirty-two 3-mo-old growing Wistar rats weighing 234 ± 2 g were assigned to a progressive isometric force, strength-training exercise program plus oral clenbuterol (2 mg · kg body wt−1 · day−1) for 5 days each week, exercise program without clenbuterol 5 days each week, no exercise program plus oral clenbuterol (2 mg · kg−1 · day−1) for 5 days each week, or no exercise without clenbuterol 5 days each week. At the end of 8 wk, lean mass, fat mass, and right total femoral, distal metaphyseal femoral, and diaphyseal femoral bone mineral density were measured by Hologic QDR 4500 dual X-ray absorptiometry (DEXA) technique. Left femoral bones were harvested after death on day 58, and femoral resistance was determined by three-point bending testing. We found that fat mass was decreased in rats given strength training exercise and decreased further in rats treated with clenbuterol. Lean mass was increased in clenbuterol-treated animals. Strength-training exercise appeared to have no effect on bone mineral density, serum osteocalcin, or urinary deoxypyridinoline. However, clenbuterol treatment decreased femoral length, diameter, bone mineral density, and mechanical resistance. Clenbuterol had no effect on osteocalcin but increased urinary deoxypyridinoline. We concluded that clenbuterol treatment decreased bone mineral density and increased bone resorption independent of the level of exercise rats were given.


Heliyon ◽  
2020 ◽  
Vol 6 (10) ◽  
pp. e05226
Author(s):  
Luis Henrique Chaves ◽  
Allan Fernando Giovanini ◽  
Joao Cesar Zielak ◽  
Rafaela Scariot ◽  
Carla Castiglia Gonzaga ◽  
...  

1971 ◽  
Vol 122 (5) ◽  
pp. 633-640 ◽  
Author(s):  
N. I. Swislocki ◽  
M. Sonenberg ◽  
M. Kikutani

Bovine growth hormone, subjected to DEAE-cellulose chromatography, yielded one major and several minor components. The various chromatographic fractions of bovine growth hormone were compared with the parent material for their ability to promote hormone effects in vivo and in vitro. The major component of bovine growth hormone was homogeneous by acrylamide-gel electrophoresis, rechromatography and sedimentation equilibrium. Its amino acid composition was similar to that of the parent hormone. The major component possessed all the qualitative activities present in the original heterogeneous material, including promotion of acute hypoglycaemia and hypolipaemia. In studies in vitro in adipose-tissue segments the major component of the hormone increased entry of glucose and its oxidation to CO2, conversion of glucose into glyceride glycerol, release of glycerol and incorporation of histidine into adiposetissue protein. Other chromatographic fractions of bovine growth hormone were not homogeneous and possessed some but not all of the metabolic activities attributed to the hormone preparations or its major component. Thus, the metabolic effects obtained with bovine growth-hormone preparations in vivo and in vitro can be obtained with the major homogeneous component of the hormone. This observation precludes the possibility that the metabolic effects obtained with bovine growth-hormone preparations are due to the combined actions of a number of components found therein.


Sign in / Sign up

Export Citation Format

Share Document